Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer

Sung Gwe Ahn, Yoon Jin Cha, Soon June Bae, Chanik Yoon, Hak Woo Lee, Joon Jeong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Recent studies have shown that tumors with extensive tumor-infiltrating lymphocytes (TILs) have a higher probability of pathologic complete response, even in luminal/human epidermal growth factor 2 (HER2)-negative breast cancer. We compared TIL levels and the 21-gene recurrence score (RS) in estrogen receptor (ER)-positive/HER2-negative breast cancer. Methods: We evaluated the percentage of stromal TILs in 198 ER-positive/HER2-negative patients in whom RS was obtained by examining slides of surgical specimens by standardized methodology proposed by the international TIL Working Group. TIL levels were categorized as high (≥ 60%), intermediate (11-59%), or low (≤ 10%). All tumors were treatment-naïve. Results: Ninety-seven (49.0%), 88 (44.4%), and 13 patients (6.6%) had low, intermediate, and high TIL levels, respectively. There was a significant but weak correlation between continuous RS and continuous TIL levels (Pearson's R=0.201, p=0.004). The mean RS was significantly highest in high TIL tumors (17.8±10.7 in low TIL tumors, 19.4±8.7 in intermediate TIL tumors, and 26.2±8.2 in high TIL tumors; p=0.014). However, when we compared categorized RS and TIL levels, we found that tumors with high TIL levels tended to have higher RS (≥ 26) but it was not significant (p=0.155). Furthermore, multivariate analysis revealed that high RS was not an independent factor associated with high TIL levels. Chemo-endocrine therapy was more frequently performed among patients with high TILs and less frequently among those with low or intermediate TILs (p< 0.001). Conclusions: Despite of a weak correlation between continuous TIL levels and RS, we found that tumors with high TIL levels tended to have a higher RS in ER-positive/HER2-negative breast cancer. Further study is warranted considering the clinical outcomes.

Original languageEnglish
Article number320
JournalBMC cancer
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 Mar 24

Fingerprint

Tumor-Infiltrating Lymphocytes
Epidermal Growth Factor
Estrogen Receptors
Breast Neoplasms
Recurrence
Genes
Neoplasms

All Science Journal Classification (ASJC) codes

  • Genetics
  • Oncology
  • Cancer Research

Cite this

Ahn, Sung Gwe ; Cha, Yoon Jin ; Bae, Soon June ; Yoon, Chanik ; Lee, Hak Woo ; Jeong, Joon. / Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer. In: BMC cancer. 2018 ; Vol. 18, No. 1.
@article{98f7c9ced88848648bfa6fd7d6872578,
title = "Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer",
abstract = "Background: Recent studies have shown that tumors with extensive tumor-infiltrating lymphocytes (TILs) have a higher probability of pathologic complete response, even in luminal/human epidermal growth factor 2 (HER2)-negative breast cancer. We compared TIL levels and the 21-gene recurrence score (RS) in estrogen receptor (ER)-positive/HER2-negative breast cancer. Methods: We evaluated the percentage of stromal TILs in 198 ER-positive/HER2-negative patients in whom RS was obtained by examining slides of surgical specimens by standardized methodology proposed by the international TIL Working Group. TIL levels were categorized as high (≥ 60{\%}), intermediate (11-59{\%}), or low (≤ 10{\%}). All tumors were treatment-na{\"i}ve. Results: Ninety-seven (49.0{\%}), 88 (44.4{\%}), and 13 patients (6.6{\%}) had low, intermediate, and high TIL levels, respectively. There was a significant but weak correlation between continuous RS and continuous TIL levels (Pearson's R=0.201, p=0.004). The mean RS was significantly highest in high TIL tumors (17.8±10.7 in low TIL tumors, 19.4±8.7 in intermediate TIL tumors, and 26.2±8.2 in high TIL tumors; p=0.014). However, when we compared categorized RS and TIL levels, we found that tumors with high TIL levels tended to have higher RS (≥ 26) but it was not significant (p=0.155). Furthermore, multivariate analysis revealed that high RS was not an independent factor associated with high TIL levels. Chemo-endocrine therapy was more frequently performed among patients with high TILs and less frequently among those with low or intermediate TILs (p< 0.001). Conclusions: Despite of a weak correlation between continuous TIL levels and RS, we found that tumors with high TIL levels tended to have a higher RS in ER-positive/HER2-negative breast cancer. Further study is warranted considering the clinical outcomes.",
author = "Ahn, {Sung Gwe} and Cha, {Yoon Jin} and Bae, {Soon June} and Chanik Yoon and Lee, {Hak Woo} and Joon Jeong",
year = "2018",
month = "3",
day = "24",
doi = "10.1186/s12885-018-4228-6",
language = "English",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer. / Ahn, Sung Gwe; Cha, Yoon Jin; Bae, Soon June; Yoon, Chanik; Lee, Hak Woo; Jeong, Joon.

In: BMC cancer, Vol. 18, No. 1, 320, 24.03.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer

AU - Ahn, Sung Gwe

AU - Cha, Yoon Jin

AU - Bae, Soon June

AU - Yoon, Chanik

AU - Lee, Hak Woo

AU - Jeong, Joon

PY - 2018/3/24

Y1 - 2018/3/24

N2 - Background: Recent studies have shown that tumors with extensive tumor-infiltrating lymphocytes (TILs) have a higher probability of pathologic complete response, even in luminal/human epidermal growth factor 2 (HER2)-negative breast cancer. We compared TIL levels and the 21-gene recurrence score (RS) in estrogen receptor (ER)-positive/HER2-negative breast cancer. Methods: We evaluated the percentage of stromal TILs in 198 ER-positive/HER2-negative patients in whom RS was obtained by examining slides of surgical specimens by standardized methodology proposed by the international TIL Working Group. TIL levels were categorized as high (≥ 60%), intermediate (11-59%), or low (≤ 10%). All tumors were treatment-naïve. Results: Ninety-seven (49.0%), 88 (44.4%), and 13 patients (6.6%) had low, intermediate, and high TIL levels, respectively. There was a significant but weak correlation between continuous RS and continuous TIL levels (Pearson's R=0.201, p=0.004). The mean RS was significantly highest in high TIL tumors (17.8±10.7 in low TIL tumors, 19.4±8.7 in intermediate TIL tumors, and 26.2±8.2 in high TIL tumors; p=0.014). However, when we compared categorized RS and TIL levels, we found that tumors with high TIL levels tended to have higher RS (≥ 26) but it was not significant (p=0.155). Furthermore, multivariate analysis revealed that high RS was not an independent factor associated with high TIL levels. Chemo-endocrine therapy was more frequently performed among patients with high TILs and less frequently among those with low or intermediate TILs (p< 0.001). Conclusions: Despite of a weak correlation between continuous TIL levels and RS, we found that tumors with high TIL levels tended to have a higher RS in ER-positive/HER2-negative breast cancer. Further study is warranted considering the clinical outcomes.

AB - Background: Recent studies have shown that tumors with extensive tumor-infiltrating lymphocytes (TILs) have a higher probability of pathologic complete response, even in luminal/human epidermal growth factor 2 (HER2)-negative breast cancer. We compared TIL levels and the 21-gene recurrence score (RS) in estrogen receptor (ER)-positive/HER2-negative breast cancer. Methods: We evaluated the percentage of stromal TILs in 198 ER-positive/HER2-negative patients in whom RS was obtained by examining slides of surgical specimens by standardized methodology proposed by the international TIL Working Group. TIL levels were categorized as high (≥ 60%), intermediate (11-59%), or low (≤ 10%). All tumors were treatment-naïve. Results: Ninety-seven (49.0%), 88 (44.4%), and 13 patients (6.6%) had low, intermediate, and high TIL levels, respectively. There was a significant but weak correlation between continuous RS and continuous TIL levels (Pearson's R=0.201, p=0.004). The mean RS was significantly highest in high TIL tumors (17.8±10.7 in low TIL tumors, 19.4±8.7 in intermediate TIL tumors, and 26.2±8.2 in high TIL tumors; p=0.014). However, when we compared categorized RS and TIL levels, we found that tumors with high TIL levels tended to have higher RS (≥ 26) but it was not significant (p=0.155). Furthermore, multivariate analysis revealed that high RS was not an independent factor associated with high TIL levels. Chemo-endocrine therapy was more frequently performed among patients with high TILs and less frequently among those with low or intermediate TILs (p< 0.001). Conclusions: Despite of a weak correlation between continuous TIL levels and RS, we found that tumors with high TIL levels tended to have a higher RS in ER-positive/HER2-negative breast cancer. Further study is warranted considering the clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85044387816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044387816&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-4228-6

DO - 10.1186/s12885-018-4228-6

M3 - Article

C2 - 29573739

AN - SCOPUS:85044387816

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 320

ER -